

Table 12.6a
Immunosuppression Use for Induction, 2000 to 2009
Recipients with Lung Transplants

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Transplants	977	1,083	1,054	1,099	1,185	1,407	1,406	1,471	1,478	1,661
With Immunosuppression Info	951	1,065	1,030	1,088	1,163	1,365	1,371	1,418	1,436	1,627
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	11.9%	8.8%	6.4%	4.9%	5.4%	3.9%	5.8%	5.8%	7.1%	6.6%
OKT3	2.6%	1.0%	0.6%	1.1%	0.5%	1.0%	1.3%	1.0%	0.7%	0.7%
Thymoglobulin	6.0%	5.4%	8.3%	3.0%	3.7%	3.0%	3.9%	4.2%	4.5%	5.1%
Zenapax	14.6%	11.3%	13.9%	15.7%	14.7%	12.6%	15.7%	16.2%	14.0%	15.9%
Simulect	8.3%	12.8%	15.0%	19.6%	23.0%	18.2%	24.5%	26.1%	28.9%	26.7%
Campath	0.0%	0.0%	0.0%	0.9%	3.6%	5.2%	7.1%	9.7%	9.2%	7.8%
No Induction Drugs Recorded	57.0%	61.1%	56.1%	55.8%	49.9%	56.8%	42.7%	37.5%	37.3%	38.7%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.